The Power of Prevention: Detecting Diabetes Before It Strikes


SAN DIEGO, Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics.

QuidelOrtho Corporation

In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority. With diabetes affecting millions of people worldwide – many undiagnosed until complications arise – early testing offers a critical opportunity to shift care from reactive to proactive. Dr. Ding shares how modern laboratory platforms and emerging biomarkers are helping clinicians intervene sooner, personalize care and prevent long-term harm.

Key insights include:

  • Early action saves lives: Detecting diabetes before complications occur changes the patient's health trajectory.
  • Beyond glucose: Emerging biomarkers like C-peptide, pro-insulin and adiponectin offer a more complete metabolic picture.
  • Smarter labs, faster answers: Automation-ready platforms deliver reliable results quickly, supporting timely clinical decisions.
  • Economic impact: Early testing reduces costly interventions and aligns with value-based care models.
  • Equity in care: Tailored testing strategies ensure accurate diagnosis across diverse populations.

This episode underscores how collaboration between labs and clinicians can help close the loop between diagnostics and care – empowering better outcomes and healthier futures.

The QuidelOrtho Science Bytes podcast is available on major streaming platforms and at: https://www.quidelortho.com/global/en/resources/podcasts/quidelortho-science-bytes.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to lab, clinic to hospital. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com 

Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
Media@QuidelOrtho.com

Episode 53: QuidelOrtho Science Bytes

Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-power-of-prevention-detecting-diabetes-before-it-strikes-302621120.html

SOURCE QuidelOrtho Corporation

Werbung

Quidel Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Quidel nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
22.01.18 Quidel Overweight Barclays Capital
18.07.17 Quidel Buy Canaccord Adams
25.04.17 Quidel Hold Canaccord Adams
08.01.16 Quidel Buy Canaccord Adams
02.09.15 Quidel Overweight Barclays Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.